In our study, the surface markers of malignant B cells obtained from the literature were compared with those of the MM group with CD38(+), 138(+), CD56(+), CD19(-) B cell separation of the control group using CD38(+), 138(+), CD56(-), CD19(+) surface markers by multicolor flow cytometry (11). This evidence concerns the gene CD38 and Miyoshi myopathy.